The formation and secretion of coagulation Factor X/Xa by mouse peritoneal macrophages was studied with a luminogenic peptide substrate (S-2613; t-butyloxycarbonylisoleucylglutamyl-y-piperidylglycylarginylisoluminol). Amidolysis was quantified by measuring the light emitted during oxidation of isoluminol, released by Factor Xa. A lower detection limit of about 0.5 ng of Factor Xa was established; the assay was linear with enzyme concentration up to at least lOOng/ml. Factor X was determined after treatment with the Factor X-activating component of Russell's-viper (Vipera russelli) venom. Macrophages, cultured in the absence of serum, released Factor X/Xa into the culture medium. The concentration of coagulation enzyme in the medium increased in an essentially linear fashion over a period of at least 3 days, at a rate corresponding to 6-8 ng produced/24 h per 106 cells. The ratio of Factor Xa/X + Xa varied from about 60 to 100%, showing that activation of Factor X to Xa is not prerequisite to release of the enzyme from the cells. Factor Xa activity was suppressed in the presence of warfarin [3-(a-acetonylbenzyl)-4-hydroxycoumarin; 12.5,ug/ml of medium], but could be restored by adding vitamin K (0.l,ug/ml) along with the warfarin. Cultures to which Sepharose beads containing covalently bound anti-(Factor X) antibodies had been added showed decreased amounts of free Factor X/Xa in the culture medium. The missing activity could be demonstrated by incubating the recovered conjugate with the substrate peptide S-2613. Factor Xa produced by the macrophages was efficiently inactivated by heparin in the presence of antithrombin, heparin with high affinity for antithrombin being more effective than the corresponding low-affinity species.
The coagulation of blood involves the sequential activation of a series of serine proteinases, culminating in the conversion of fibrinogen, a soluble plasma protein, into insoluble fibrin. The proteinases are synthesized in the liver and are generally contained within the circulating blood. However, the so-called extrinsic pathway of coagulation is initiated by an extravascular factor, thromboplastin or tissue factor [for a review see Jackson & Nemerson ( 1980) ]. The procoagulant properties ofmacrophages have been ascribed to the ability of these cells to produce thromboplastin and to present this initiator Abbreviations used: S-2613, t-butyloxycarbonylisoleucylglutamyl-y-piperidylglycylarginylisoluminol; RVV-X, Factor X-activating component of Russell's-viper venom. molecule at the cell surface 0sterud and E. Bj0rklid, unpublished work), after exposure to certain stimuli [for references see Geczy & Hopper (1981) ]. The expression of thromboplastin activity depends on an interaction between the macrophages and T-lymphocytes (0sterud et al., 1981) that apparently involves transfer of a stimulatory signal from the activated lymphocytes to the macrophages (Levy & Edgington, 1980; . The thromboplastin thus formed and/or exposed as a consequence of an inflammatory reaction may initiate the local deposition of fibrin, provided that the appropriate coagulation proteinases and fibrinogen are available. Increased vascular permeability that accompanies inflamma-tory reactions allows leakage of such components into the interstitial spaces.
Novel aspects on the relation of macrophages to the coagulation system emerged with the finding that mouse peritoneal macrophages produce not only thromboplastin but also the vitamin K-dependent coagulation Factors VII, IX and X and prothrombin, as well as Factor V (0sterud et al., 1980, 1981) . Taken together, these proteins constitute all the components involved in the extrinsic coagulation pathway. Secretion of coagulation enzymes by macrophages in vitro was initially detected by spectrophotometric determination of p-nitroaniline released from chromogenic peptide substrates added to culture media , and subsequently confirmed by using specific one-stage clotting assays (0sterud et al., 1980) . However, neither of these assays could be adopted to a more detailed characterization of the coagulation factors; the former system lacked sensitivity, the latter accuracy. In the present investigation the secretion and some properties of Factor X/Xa from mouse peritoneal macrophages were studied by using a highly sensitive assay based on a luminogenic peptide substrate.
Experimental

Materials
The luminogenic peptide substrate S-2613 was kindly donated by Dr. Leif Aurell, AB Kabi Peptide Research, M6lndal, Sweden. Stock solutions (0.1 mM) were stored at -700C.
Coagulation Factor X was isolated from human plasma (0sterud & Rapaport, 1977) ; Factor Xa was obtained by activating Factor X with Russell's-viper (Vipera russelli) venom (Lindquist et al., 1978) . The Factor X-activating component of Russell's-viper venom (RVV-X), purified as described by Kisiel et al. (1976) , and bovine antithrombin, were kindly given by Dr. I. Bjork of one of our institutions (Uppsala). The heparin preparations used were as described by Bengtsson et al. (1980) . fl1,3-Glucan from Saccharomyces cerevisiae (baker's yeast) was isolated as described by Manners et al. (1973) . Goat anti-(human-Factor X) antibodies (active also against Factor Xa) were prepared (Seligsohn et al., 1979) and covalently bound to Sepharose 2B (March et al., 1974 
Methods
Macrophages from hybrid C3D2 (C3H/ Tif Y x DPB/2 J) mice were collected by peritoneal washing with phosphate-buffered saline (Cohn & Benson, 1965) . Cells were seeded in either 16mm wells in Costar plastic plates (Costar, Broadway, Cambridge, MA, U.S.A.; 0.7x 106 cells/well in 0.5 ml of medium) or in Falcon plastic dishes (Falcon, Oxnard, CA, U.S.A.; 3 x 106 cells/well in 1 ml of medium). The cells were cultured in Medium 199 with Earle's salts (Gibco Bio-cult, Paisley, Scotland, U.K.) supplemented with human albumin (0.4 mg/ml), human transferrin (lO,ug/ml), vitamin K (0.1,ug/ml, unless otherwise stated); and 100i.u. of penicillin and streptomycin/ml. Human albumin and transferrin had been treated as described by Iscove & Melchers (1978) . Incubations were conducted in a humidified atmosphere of C02/air (1:19) at 37°C. Non-adherent cells were washed away after 2h in culture. The media were routinely collected after 24h of incubation, centrifuged at SOOg for 10min and stored at -70°C until analysed. In some experiments, anti-(Factor X)-Sepharose conjugate was added to the culture as described in the Results section.
For assays of Factor Xa, lOO,l of culture medium was mixed with 50ul of 0.05 M-Tris/HCl, pH8.0, containing 0.15M-NaCl and 3OmM-CaCI2, in plastic Ellerman tubes. After the addition of 5O,ul of 0.1 mM-S-26 13, the reaction mixtures were incubated in a water bath at 370C for 15min. Inactive Factor X was determined in parallel incubations containing SOng of RVV-X; these samples were preincubated for 5 min before the addition of S-2613 in order to convert any Factor X present into Xa. After the 15min reaction period, amidolysis was interrupted by adding 20,u1 of 20% acetic acid. The liberated isoluminol was determined by chemiluminescence measurements, using a Lumac Biocounter M2010 luminescence photometer. From each incubation mixture samples of 50,ul were transferred to cuvettes containing 0.7ml of 0.05 M-NaOH and 25,ul of 25,uM-haemin. Immediately after mixing, the cuvettes were placed in the counting chamber of the photometer and the luminescent reaction (oxidation of isoluminol; see Roswell & White, 1978) was initiated by injecting lOO,ul of 8OguM-H202. The light emitted was monitored over a 30s period, during which the reaction was essentially completed. Assays were performed in triplicate with an error (s.D./mean) of 5%.
In order to determine the effects of heparin and antithrombin on Factor Xa activity these components were added to the incubation mixtures for a 3min preincubation period before the addition of S-2613. Polybrene (NNN'N'-tetramethylhexane-1,6-diamine polymer with 1,3-dibromopropane; 2,ug) was added along with the substrate to bind free heparin.
Results
Assay ofFactor X/Xa
Luminogenic peptides with isoluminol as chemiluminescent leaving groups have been previously employed in studies on serine proteinases such as trypsin, chymotrypsin and thrombin (Branchini et al., 1980) . In the cited study, background light emission of unchanged substrate was considered a seri6us limitation to the potentially greater sensitivity of luminescence over absorbance-or fluorescence-based methods, and was therefore eliminated by use of immobilized substrates that could be removed by centrifugation after incubation with the enzymes. In the present work the background emission, although considerable (see the legend to Fig. 1 ), did not interfere to any significant extent with the determination of Factor X/Xa, in the concentrations relevant to the test system studied. Under the conditions of the assay the release of isoluminol by Factor Xa from the substrate, S-26 13, remained linear with time over a period of 60min (result not shown). After a 15 min incubation period, the amount of free isoluminol was proportional to enzyme concentration, up to at least lOOng/ml (Fig.  1) . Although the presence of RVV-X had no effect on the reaction with Factor Xa (Fig. la) , it was a prerequisite to activity with Factor X (Fig. 1 b) without RVV-X respectively in the incubations. The lower limit of detection for Factor Xa corresponded to about 5 ng/ml (0.5 ng/0. 1 ml of sample). The luminogenic substrate thus affords an approx. 100-fold increase in sensitivity compared with chromogenic substrates.
Secretion ofFactor X/Xa by macrophages Medium collected from a 24h culture of mouse peritoneal macrophages catalysed the cleavage of the luminogenic peptide substrate, S-2613 (Fig. 2) ing anti-(Factor X)-Sepharose beads, the total X/Xa activities associated with the antibodies were in fair agreement with those expected from a comparison with a control culture lacking antibodies against Factor X (Fig. 3) . Furthermore, in experiments where the control culture showed only partial activation of Factor X into Factor Xa, a significant proportion of the material bound to the immobilized antibodies could be activated by treatment with RVV-X.
Cultured mouse peritoneal macrophages continuously release Factor X/Xa into the medium over a period of at least 3 days (Fig. 4) . The amounts produced and secreted over a 24h culture period would correspond to approx. 6-8ng/106 cells. In cultures maintained under standard conditions, the ratio of activated Factor Xa to native Factor X in the culture media varied from one experiment to another, in a seemingly non-systematic manner. With some cell preparations, such as that used in the experiment illustrated in Fig. 4(a) , the native factor consistently accounted for a major proportion, up to 30-40%, of the total Factor X/Xa secreted into the medium. Activation of Factor X is thus not a prerequisite to its release from the macrophage. However, with other cell preparations, isolated under virtually identical conditions, treatment with RVV-X failed to increase the Xa activity of spent medium (not shown in the Figure) . Nevertheless, a correlation of the X/Xa ratio to the functional state of the peritoneal cells were maintained either (Fig. 4a) Effect of heparin and antithrombin produced by macrophages The Factor Xa produced by mac further studied with regard to the e thrombin and heparin (Fig. 5) . Under of the assay, antithrombin alone (1 ,ug Xa activity of spent culture medium Heparin with high affinity for antithi potentiated the effect of the inhibitor addition of 0. lug resulted in almost cl activity. Significant inhibitory effect with less than 1 ng of polysaccharide low affinity for antithrombin also r inhibition of Factor Xa, but was aboi magnitude less potent than the high-a These findings conform to the gene (Nordenman et al., 1980) . Furthermore, at higher heparin concentrations (1 pg/incubation mixture), significant inhibition of Factor Xa was noted, even in the absence of added antithrombin, highaffinity heparin again being more potent than low-affinity heparin (Fig. 5) Rick, 1977; Prydz & Allison, 1978; Levy & Edgington, 1980; Levy et al., 1981; culture. The results shown in Fig. 4(a) are not in accord with such a concept, but rather suggest that Factors X and Xa are both secreted as such without any further conversion of Factor X into Xa.
However, more refined quantitative data are required to settle this matter. Numerous observations have appeared in the literature linking the coagulation system to various types of inflammatory reactions involving the immune system (for references, see Levy & Edgington, 1980; . Extravascular fibrin deposition is often a prominent feature of such reactions. Fairly recently, interaction between stimulated lymphocytes and macrophages was found to result in the deposition of fibrin on the macrophage cell surface and in changed functional properties of these cells . It seems reasonable to assume that the procoagulant properties displayed in this manner by the macrophages reflect not only the production of thromboplastin, but also the formation of the actual coagulation enzymes by the same cells. The overall process, which may thus be regarded as an expression of an inflammatory reaction, is liable to regulation at various levels. Two potential regulatory mechanisms, with support in experimental data, are illustrated in Scheme 1. The formation of thromboplastin, presumably essential for the activation of Factor X, appears to be under control of lymphocytes; mechanisms based either on direct contact between lymphocytes and macrophages (Levy & Edgington, 1980) , or on lymphokine action , have been postulated. An opposing effect is exerted by heparin released from mast cells; in the present study, heparin, together with antithrombin, was found to effectively inhibit Factor Xa produced by the macrophages.
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